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ABSTRACT 
Chronic kidney disease (CKD) is a global health burden of growing incidence and 
prevalence. As renal function declines disturbances in mineral metabolism, such as 
hyperphosphatemia and secondary hyperparathyroidism, inevitably develop. These 
metabolic changes are closely associated with poor prognosis and survival. The bone-
derived hormone fibroblast growth factor-23 (FGF23) and its co-receptor Klotho 
represent a novel endocrine axis regulating mineral metabolism in health and disease. 
FGF23-Klotho signalling inhibits renal phosphate reabsorption and activation of 
vitamin D, and reduces secretion of parathyroid hormone (PTH). Serum levels of 
FGF23 rise at early stages of CKD, presumably due to increased phosphate load, and 
numerous studies identify elevated FGF23 as a predictor of adverse clinical outcome. 
In contrast, tissue expression of Klotho decreases in parallel with CKD progression and 
reaches low or undetectable levels in end-stage renal disease. Importantly, mice lacking 
Klotho develop numerous complications associated with accelerated ageing, and many 
patients with advanced CKD, a state of Klotho deficiency, display a similar senescence-
like phenotype. Altogether, FGF23 excess and lack of Klotho may be key pathogenic 
factors in CKD. In the present thesis we sought to elucidate the role of renal and 
parathyroid FGF23-Klotho signalling in physiology and in CKD. 
In Study I we investigate Klotho levels in surgically resected parathyroid 
tissue specimen from CKD patients with secondary hyperparathyroidism, and find 
diminished Klotho expression paralleling the decline in renal function. Further, we 
demonstrate that FGF23 dose-dependently suppresses Klotho in bovine parathyroid cell 
culture, indicating a ligand-receptor regulatory process. 
In Study II we generate parathyroid-specific Klotho knockout mice 
(PTH-KL-/-) using Cre-Lox recombination. PTH-KL-/- mice display a normal gross 
phenotype with a preserved calcium-PTH axis. Their PTH response is similar to wild-
type mice when treated with FGF23 or challenged with renal failure. Yet, FGF23 
treatment activates the MAPK pathway in wild-type mice but not in PTH-KL-/- mice. 
Importantly, blocking of calcineurin with cyclosporine A abolishes the FGF23-
mediated PTH suppression in PTH-KL-/- mice, whereas wild-type mice remain 
responsive. Thus, we identify a novel calcineurin-dependent pathway in the parathyroid 
glands that, in the absence of Klotho, mediates acute suppression of PTH secretion by 
FGF23. 
In Study III we develop a novel, non-surgical, mouse model of 
tubulointerstitial nephropathy. By adding various concentrations of adenine to the diet 
we define an adjustable protocol for inducing and maintaining uremia in mice. 
In Study IV we generate distal tubule-specific Klotho knockout mice 
(Ksp-KL-/-). In contrast to systemic Klotho knockout mice, Ksp-KL-/- mice are fertile 
with a normal gross phenotype. Adult Ksp-KL-/- mice are hyperphosphatemic, 
indicating attenuated effects of FGF23 on proximal tubular phosphate handling. 
Further, FGF23 is higher in Ksp-KL-/- mice than in wild-type mice with matched serum 
phosphate, suggesting phosphate-independent regulation of FGF23 in Ksp-KL-/- mice.  
Collectively, the studies presented in this thesis identify several novel and 
critical aspects of FGF23-Klotho signalling and function in health and disease, and 
provide important tools allowing for continuous investigation. 
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1 INTRODUCTION 
 
1.1 MINERAL METABOLISM 
Calcium and phosphate are vital in a number of biological systems, including bone 
formation, energy metabolism, different metabolic pathways and intracellular 
signalling. Accordingly, their endocrine regulation is a tightly controlled process, and 
involves several hormones and feedback loops. In physiology, mineral homeostasis is 
achieved through a balance between intestinal absorption, bone influx and efflux, and 
renal excretion.  
Disturbances in mineral metabolism are implicated in various skeletal, 
metabolic and endocrine disorders1,2. In the community, abnormalities in calcium and 
phosphate are commonly seen in individuals with impaired renal function. Importantly, 
high serum phosphate and calcium x phosphate product are independent risk factors for 
cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD), 
as well as in healthy individuals3-5. 
In recent years, the identification of a novel endocrine axis comprising 
fibroblast growth factor-23 (FGF23) and αKlotho (Klotho) has lead to a paradigm shift 
in the understanding of mineral metabolism. 
 
 
1.1.1 Calcium homeostasis 
Calcium (Ca) is the fifth most abundant element in the human body and is critical for a 
diverse range of biological processes ranging from bone metabolism and muscle 
contraction to intracellular signalling. It is an essential element and only available 
through dietary sources. The daily need depends on gender and age, and varies from 
approximately 600 mg to 1200 mg. In growing people the calcium balance is positive 
to allow high bone formation, whilst in the elderly the calcium balance is commonly 
negative with decreased bone formation and reduced bone mass. Calcium homeostasis 
is regulated through an intricate interplay between factors acting on the intestine, bone, 
kidneys and parathyroid glands6. The main calcium-regulating systems are parathyroid 
hormone (PTH) acting on the G protein-coupled parathyroid hormone receptor 
(PTH1R) and 1,25 dihydroxyvitamin D (1,25(OH)2D) acting on the nuclear vitamin D 
receptor (VDR).  
 
1.1.1.1 Calcium and parathyroid hormone 
A decrease in serum calcium rapidly inactivates the parathyroid gland resident calcium-
sensing receptor (CaSR), leading to increased secretion of preformed PTH from 
parathyroid chief cells7. PTH is an 84 amino acid polypeptide that acts on distal tubular 
PTH1R to increase renal calcium reabsorption, and on skeletal PTH1R to increase bone 
resorption. Low calcium ion concentration also directly inactivates CaSR in the thick 
ascending limb of the renal tubule to further increase active calcium reabsorption. If the 
low calcium levels persist for an extended time there is an upregulation in PTH mRNA 
transcription and eventually an increase in parathyroid cell proliferation. In contrast, 
high serum calcium activates CaSR and leads to a rapid decrease in secretion of PTH, 
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subsequently resulting in increased renal calcium loss, decreased bone resorption and 
decreased intestinal calcium absorption. The relationship between serum calcium and 
PTH forms a sigmoidal curve where relatively small changes in calcium concentration 
evoke large responses in PTH secretion.8  
 
1.1.1.2 Calcium regulation by vitamin D 
Vitamin D can either be ingested with the diet or synthesized in the skin when exposed 
to UVB radiation. It is subject to 25-hydroxylation in the liver to 25 hydroxyvitamin D 
(25(OH)D), and later 1-hydroxylated by renal 25-dihydroxyvitamin D 1-alpha-
hydroxylase (CYP27B1) to 1,25(OH)2D, the biologically active form. In an intricate 
feedback system CYP27B1 is induced by PTH, hypocalcemia and hypophosphatemia, 
and repressed by hypercalcemia and hyperphosphatemia. VDR activation in the 
parathyroid gland decreases PTH synthesis and secretion, and also upregulates CaSR to 
make the chief cells more susceptible to inhibition by calcium. In the distal tubule 
1,25(OH)2D facilitates calcium uptake by increasing the abundance of transient 
receptor potential cation channel, subfamily V, member 5 (TRPV5) on the apical 
membrane and by making the tubule cells more susceptible to PTH-mediated calcium 
reabsorption9. VDR activation also facilitates calcium uptake in the small intestine and 
increases calcium release from bone through activation of osteoclasts, and under 
conditions of high calcium demand e.g. lactation, also from osteocytes. Of note, also 
25(OH)D binds to and activates VDR, although with a 1000-fold lower affinity than 
1,25(OH)2D10. 
 
 
1.1.2 Phosphate homeostasis 
Phosphorous (P) is the sixth most common element in humans and comprise 
approximately 1.4% of the body mass. It is virtually never in its elemental form, and in 
the body it is predominantly bound to oxygen as phosphate (PO43-). Phosphate is 
required for all forms of life and plays a crucial role in energy metabolism as part of 
adenosine triphosphate (ATP), in biological molecules such as DNA and RNA and in 
the cellular membrane as a constituent of phospholipids. The vast majority of 
phosphate (approximately 80%) is tied to mineralized tissue, predominantly bone and 
teeth, in the form of hydroxyapatite ([Ca]5[PO4]3[OH]). The remainder is distributed in 
skeletal muscles and in extracellular compartments. Phosphate homeostasis is similarly 
to calcium maintained by several factors affecting intestinal absorption, renal 
reabsorption and skeletal metabolism. The physiological range for serum phosphate is 
wider than for calcium, changes are better tolerated and the adaptive mechanisms much 
less rapid.  
 
1.1.2.1 Intestinal phosphate absorption 
Absorption of phosphate takes place in the small intestine through both passive 
diffusion and active transport by the sodium-dependent phosphate transporter Npt2b. 
High dietary phosphate intake increases the passive paracellular uptake while active 
transport of phosphate is induced by 1,25(OH)2D, increasing the abundance of the 
sodium-dependent phosphate co-transporter Npt2b on the luminal side of enterocytes. 
The exact contribution of passive versus active transport of phosphate is not known, but 
recent animal studies emphasize the significance of active transport11.  
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1.1.2.2 Renal phosphate handling 
The kidneys are key organs in phosphate regulation and adequate renal handling of 
phosphate is essential in maintaining a neutral balance. Phosphate is filtered freely in 
the glomerulus and the reabsorption in proximal tubules adapts in response to 
endocrine regulation. Under physiological conditions, around 70% of the filtered 
phosphate is reabsorbed. The rate of reabsorption can be increased during low 
phosphate conditions, and is determined mainly by the apical brush-border abundance 
of the sodium-dependent phosphate co-transporters Npt2a and Npt2c. Npt2a and Npt2c 
are expressed predominantly in the early segments of the proximal tubule and accounts 
for approximately 80% and 20% of the active reabsorption respectively12. 
 
1.1.2.3 Phosphate and the bone 
In addition to the intestine and kidneys, bone plays an important role in phosphate 
metabolism. Phosphate is a crucial component in the matrix mineralization process by 
osteoblasts and osteocytes. Conversely, as the main repository for phosphate the 
skeleton can adapt to changes in the demand of extracellular phosphate through altered 
bone remodelling.  
 
1.1.2.4 Phosphate regulation 
Until recently PTH was considered the principal hormone responsible for maintaining 
phosphate homeostasis. High serum phosphate increases PTH secretion independently 
of serum calcium and 1,25(OH)2D13. In turn, PTH reduces Npt2a and Npt2c at the 
apical brush-border membrane through internalization and subsequent degradation, thus 
increasing urinary phosphate loss14. On the other hand, PTH signalling leads to 
increased phosphate efflux from the bone by enhanced resorption. Additionally, PTH 
increases phosphate uptake in the small intestine indirectly through activation of 
CYP27B1. Despite its actions on bone and intestine to increase phosphate, the 
aggregate effect of PTH is a decrease in serum phosphate, and PTH should therefore be 
regarded as a phosphate-lowering hormone. Although the existence of a phosphate-
sensing receptor has been proposed, the mechanism by which phosphate-regulating 
hormones adapt to changes in serum phosphate remains unclear15. The identification of 
FGF23 and Klotho represents a paradigm shift in the understanding of phosphate 
regulation, and is described in detail in subsequent chapters. 
 
 
1.1.3 Fibroblast growth factor-23 
1.1.3.1 Fibroblast Growth Factors and Fibroblast Growth Factor Receptors 
Fibroblast growth factors (FGFs) are a highly conserved family of genes organized into 
seven subfamilies. The 22 genes encode molecules with the capability of binding one 
or several fibroblast growth factor receptors (FGFRs)16. This overlap in specificity 
commonly leads to receptor redundancy, where absence of one FGFR can be 
compensated by others. Of note, alternative splicing of the four FGFR genes results in 
almost 50 different isoforms of FGFR. Binding of the ligand to a receptor dimer of two 
FGFRs evokes a signal transduction with a plethora of downstream effects. FGF 
signalling activates several common pathways, including MAPK and PLCγ17,18. In 
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contrast to other FGFs’ intracrine or paracrine actions, the FGF19 subfamily members 
(FGF19, FGF21 and FGF23) act as endocrine factors19.  
 
1.1.3.2 FGF23 structure 
The FGF23 gene is located on chromosome 12 and composed of three exons encoding 
a 251 amino acid protein (Figure 1A). The 32 kDa protein is mainly produced by 
osteocytes and osteoblasts in bone20,21. FGF23 contains several glycosylation sites and 
is O-glycosylated by Polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) to 
prevent preterm proteolytic cleavage. The full-length FGF23 protein is cleaved at 
position 176RXXR179 by an unknown subtilisin-like pro-protein convertase into one 18 
kDa N-terminal and one 12 kDa C-terminal fragment22. These fragments do not 
activate FGFRs, but recent data indicate that the C-terminal fragment may act as a 
competitive inhibitor to full-length FGF2323. However, the physiological relevance of 
the FGF23 fragments is unknown.  
 
1.1.3.3 FGF23 function 
In the kidney FGF23 decreases reabsorption of phosphate in the proximal tubule by 
down-regulating Npt2a and Npt2c24. FGF23 also inhibits the vitamin D activating 
enzyme CYP27B1 and increases the catabolism of vitamin D through activation of 
1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1), altogether resulting in lower 
levels of circulating 1,25(OH)2D25. In the parathyroid gland FGF23 decreases the 
synthesis and secretion of PTH, and in contrast to the kidney induces expression of 
CYP27B126,27. 
 
1.1.3.4 Human disorders 
FGF23 was originally identified as the causative factor in patients with autosomal 
dominant hypophosphatemic rickets (ADHR, OMIM 193100), a rare hereditary 
disorder characterized by urinary phosphate wasting and reduced bone mineralization28. 
Missense mutations at the cleavage site of FGF23 prevent processing and result in 
accumulation of the intact protein. Also in X-linked hypophosphatemia (XLH, 307800) 
and autosomal recessive hypophosphatemic rickets 1 and 2 (ARHR1 and ARHR2, 
241520 and 613312) the levels of FGF23 are abnormally elevated29. This is caused by 
mutations in the FGF23-regulating genes PHEX, DMP1 and ENPP1 respectively, but 
the molecular mechanisms behind these disorders are incompletely understood. In 
opposite, inactivating mutations in GALNT3 lead to enhanced degradation of FGF23 
due to defect glycosylation, causing hyperphosphatemic familial tumoral calcinosis 
(HFTC, 211900), a syndrome characterized by hyperphosphatemia and deposition of 
calcium-phosphate crystals in the soft tissues secondary to reduced FGF23 activity30. 
 
1.1.3.5 Mouse models 
In support of FGF23’s phosphaturic and vitamin D suppressive properties, 
overexpression of FGF23 in transgenic mice or intravenous administration of 
recombinant FGF23 causes a phenotype similar to that seen in human disorders of 
FGF23 excess with hypophosphatemia, reduced 1,25(OH)2D levels and impaired 
skeletal mineralization31-33. Conversely, FGF23 knockout mice (Fgf23-/-) display severe 
hyperphosphatemia secondary to reduced renal phosphate excretion, elevated 
1,25(OH)2D and widespread soft tissue calcifications34. 
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1.1.3.6 Regulation of FGF23 
The regulation of FGF23 has proven to be more complex than first anticipated, and is 
still incompletely understood. All key components of mineral metabolism, namely 
phosphate, calcium, vitamin D and PTH, stimulate the expression of FGF23. In 
addition, recent studies have found that iron, estrogen, leptin and glucocorticoids also 
alter FGF23 synthesis and secretion35. Activation of a vitamin D-responsive element in 
the FGF23 promoter is the most potent known stimulus for FGF23 expression, thus 
forming a classical endocrine feedback loop between FGF23 and vitamin D. 
Administration of 1,25(OH)2D dose-dependently increases transcript and serum levels 
of FGF23, which in turn suppresses 1,25(OH)2D25. Conversely, when vitamin D 
activity is abrogated through dietary means or by genetic targeting, serum FGF23 is 
virtually undetectable16,36. Since FGF23 is a phosphaturic hormone, phosphate was 
long considered to be one of its main inducers. Indeed, dietary phosphate does regulate 
FGF23, although the effects in healthy individuals are modest and have slow onset37. 
Of note, the intestine seems to play a part in phosphate-mediated FGF23 induction 
since intravenous administration of phosphate does not lead to elevated FGF23, despite 
a similar increase in serum phosphate as for dietary loading38. When summarizing 
available data there is little evidence for a direct regulation of FGF23 by phosphate, 
suggesting regulation via indirect mechanisms; speculatively through intestinal factors 
and altered bone metabolism. Emerging data indicates a central role for iron in FGF23 
processing and secretion. C-terminal FGF23 is markedly elevated in patients with iron 
deficiency, and infusion of iron-containing compounds decreases the c-terminal FGF23 
levels while intact FGF23 increases or remains unchanged39. This is supported by a 
recent study where wild-type mice exposed to a low-iron diet had elevated mRNA 
levels of FGF23 but maintained normal intact FGF23 levels through enhanced 
intracellular degradation. In contrast, mice carrying an ADHR mutation fed an iron-
deficient diet suffered from hypophosphatemia and osteomalacia secondary to 
increased levels of intact FGF2340. The cellular mechanism(s) governing transcriptional 
and posttranslational regulation of FGF23 are still largely unknown and merits further 
investigation. 
 
 
1.1.4 Klotho 
1.1.4.1 Discovery of the Klotho gene 
The Klotho gene was identified by Kuro-o et al in 1997 when studying transgenic mice 
overexpressing a sodium proton exchanger41. By accident a locus of a neighbouring 
gene was interrupted, and the mice (Klotho-/-) displayed a striking phenotype 
resembling human ageing with reduced activity, osteoporosis, vascular and soft tissue 
calcifications, pulmonary emphysema, skin atrophy and shorter lifespan. Conversely, 
overexpression of Klotho in mice led to an extended lifespan, and Klotho was therefore 
considered to be an anti-ageing gene42. The name derives from the goddess Clotho, 
daughter of Zeus and the youngest of the Three Fates or Moirai. In Greek mythology, 
Clotho spins the thread of life and decides over birth and death.  
 
1.1.4.2 Structure and isoforms of Klotho 
The KLOTHO gene is located on chromosome 13 and has five exons encoding a 1014 
amino acid protein. The Klotho protein has a short intracellular domain and two 
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extracellular tandem repeats (KL1 and KL2) with homology to beta-glucosidases. 
Membrane-bound Klotho is predominantly expressed in the kidneys distal tubule, the 
parathyroid glands and the choroid plexus of the brain43. Expression has also been 
reported in other cell types such as sinoatrial cells of the heart, monocytes and 
mesenchymal stem cells, although at low absolute levels and of uncertain physiological 
relevance44,45. The Klotho protein exists in three distinct isoforms; the 130 kDa full-
length membrane-bound form (mKL), soluble Klotho produced by ectodomain 
shedding of mKL from the cell surface (cKL), and a truncated form produced through 
alternative splicing at exon 3 that only contains the KL1 domain (sKL)(Figure 1B)43.  
 
1.1.4.3 Klotho as a co-reptor for FGF23 
Unlike most other FGFs, FGF23 lacks a heparan-sulfate-binding motif and therefore 
has low affinity to FGFRs. Interestingly, Fgf23-/- and Klotho-/- mice share almost 
identical phenotypes with reduced body size, organ atrophy, extensive soft tissue 
calcifications, reduced bone mineralization and shortened life-span. In 2006, a Japanese 
group identified mKL as an essential co-factor for FGF23 signalling, enabling high-
affinity binding to FGFR1c, 3c and 4 and subsequent activation of the MAPK pathway 
(Figure 1C)46. The indispensable role of mKL as a co-receptor for FGF23 is supported 
by the fact that Klotho-/- mice suffer from hyperphosphatemia, elevated 1,25(OH)2 D 
and reduced urinary phosphate excretion despite extreme levels of circulating FGF23. 
A similar phenotype is seen in a patient with an inactivating mutation in the KLOTHO 
gene where a markedly elevated FGF23 is unable to correct the biochemical 
disturbances due to end-organ resistance47. Since the FGFRs are ubiquitously expressed 
the tissue-specificity for FGF23 action is determined by the limited distribution of 
Klotho.  
 
1.1.4.4 FGF23-independent functions of Klotho 
In addition to its role as a co-receptor for FGF23 mKL has been proposed to facilitate 
PTH secretion at low calcium conditions through recruitment of the Na+/K+-ATPase to 
the surface of parathyroid cells48. Similarly, Klotho was found to increase abundance of 
the Na+/K+-ATPase in the collecting duct to prevent renal salt wasting and 
hypovolemia49. Although interesting, these data are controversial and the mechanisms 
of action have been challenged50.  
 
1.1.4.5 Regulation of Klotho 
Hypophosphatemia and 1,25(OH)2D both induces the renal expression of mKL51,52. In 
contrast, continuous exposure to high FGF23 in Fgf23 transgenic mice reduces mKL, 
although it is unknown if this is a direct or indirect effect53. The upstream regulators of 
Klotho shedding and alternative splicing are still largely unknown. 
 
1.1.4.6 Soluble Klotho 
cKL is cleaved off the cell surface by membrane-anchored proteases, including 
ADAM10 and 17, and acts as a hormone and an enzyme54. In an FGF23-independent 
fashion cKL reduces the proximal tubule phosphate reabsorption through enzymatic 
actions leading to enhanced endocytosis and degradation of Npt2a55. In addition, cKL 
can hydrolyze sugar residues on the renal calcium channel TRPV5 and the potassium 
channel ROMK156. The removal of sugar residues triggers interaction with Galectin-1 
and prevents endocytosis, thereby increasing the abundance of these cation channels at 
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the cell surface57. cKL also inhibits insulin and insulin-like growth factor I activity, 
corroborating with the observation that Klotho-/- mice are hypoglycemic with increased 
sensitivity to insulin42. The receptor responsible for binding cKL has yet not been 
identified, but could speculatively be a FGFR or even mKL. cKL doesn’t function as a 
co-receptor for FGF23, but has proven to be a potent stimulator of FGF23 expression. 
In a patient with a translocation in the KLOTHO gene causing increased serum cKL, 
FGF23 was markedly elevated resulting in hypophosphatemic rickets58. Likewise, mice 
overexpressing cKL have increased FGF23 levels despite persistent 
hypophosphatemia59. The notion of cKL as an inducer of FGF23 is somewhat 
paradoxical, and the physiological relevance remains uncertain.  
sKL is present in serum, urine and cerebrospinal fluid of healthy individuals, 
but the functions of sKL are not well characterized. Recent data suggest that sKL as 
well as cKL are antagonists of endogenous Wnt/β-catenin signalling, and ameliorate 
the development of renal fibrosis60. However, further investigation to determine the 
role of sKL is warranted. 
 
1.1.4.7 Quantification of soluble Klotho 
Methods for quantification of soluble Klotho (cKL and sKL) have recently been 
developed. A sandwich ELISA was established in 2010 and the first report revealed a 
graded decline with increasing age in healthy individuals. Soluble Klotho also 
correlated to serum phosphate and inversely to creatinine and FGF2361. However, 
soluble Klotho levels were unaltered in patients with XLH and elevated FGF2362. In a 
comparison of two different ELISA for soluble Klotho the outcome differed 
substantially, underlining the uncertainty of current methods and the need for 
precaution when interpreting the results63.  
 
A schematic overview of the regulation of mineral metabolism is found in Figure 2. 
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Figure 1. Fibroblast growth factor-23 (FGF23), the three isoforms of Klotho and the FGF23–FGF 
receptor (FGFR)–Klotho complex.  A) Structure of the 251 amino acid FGF23 protein, with the N-
terminal FGF homology region and the unique C-terminal receptor-binding region, allowing interaction with 
the co-receptor Klotho. The active full-length form of FGF23 can be cleaved into two inactive fragments at 
the position 176RXXR179.  B) Membrane-bound Klotho (mKL) can be cleaved of at the cell surface by 
secretases to form soluble Klotho (cKL). Another form of soluble Klotho (sKL) is generated through 
alternative splicing at exon 3. C) Intact FGF23 binds a receptor complex of Klotho and a FGFR dimer to 
activate downstream signalling, most importantly through the MAPK pathway. Adapted from Hu MC et al64.  
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Figure 2. Endocrine regulation of calcium (Ca2+) and phosphate (PO43-) metabolism. Calcium and 
phosphate are regulated through a complex interplay involving the parathyroid glands, kidneys, intestine 
and bone, and the key hormonal regulators; parathyroid hormone (PTH), fibroblast growth factor-23 
(FGF23), soluble Klotho and 1,25 dihydroxyvitamin D (1,25(OH)2D).  PTH is released from the parathyroid 
glands when serum calcium is low, and increases bone resorption and renal calcium reabsorption directly, 
and intestinal absorption indirectly through activation of 1,25(OH)2D. Klotho is released from the kidney 
and act as a phosphaturic and calciotropic hormone in the renal tubules. High serum phosphate induces 
FGF23 secretion, which in turn reduces renal phosphate reabsorption. PTH, FGF23, Klotho and 
1,25(OH)2D also regulate each other through negative feedback loops. 
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1.2 CHRONIC KIDNEY DISEASE 
1.2.1 Background 
The term chronic kidney disease (CKD) is defined by the presence of renal damage 
(often quantified by albuminuria) and/or decreased glomerular filtration rate (GFR 
below 60 mL/min/1.73 m2) for more than three months, irrespective of underlying 
aetiology. It is classified into five stages based on GFR65.  The most common 
underlying pathology of CKD is diabetic glomerulosclerosis, followed by vascular 
disease/hypertensive nephrosclerosis and glomerular disease. Today CKD is a major 
health concern affecting 5-10% of the population globally, and as many as 15% in 
Europe and in the United States (Table 1)66,67. The global incidence and prevalence of 
CKD is growing, mainly attributed to the ageing population and the concomitant 
increase in CKD risk factors, such as hypertension and diabetes. The age-adjusted 
mortality risk is increased already in early stages of CKD and increases further as the 
deterioration in renal function progresses68. In patients with CKD stage 5, also called 
end stage renal disease (ESRD), the five-year survival rate is approximately 50%5. The 
incidence and prevalence of cardiovascular disease (CVD) is dramatically increased in 
patients with renal dysfunction, and CVD is one of the leading causes of mortality in 
CKD69. Current therapies in CKD are targeted at the multiplicity of factors known to be 
associated with disease progression and mortality, including albuminuria, hypertension, 
hyperphosphatemia, secondary hyperparathyroidism (sHPT) and activation of the 
Renin-Angiotensin-Aldosterone system (RAAS). Renal replacement, i.e. dialysis or 
kidney transplantation, are life saving therapies in end stage CKD. Yet, the reduced 
long-term survival and risk for cardiovascular complications in the uremic setting are 
discouraging and new effective treatment strategies for patients in all stages of CKD 
are much needed. 
 
 
Stage Description GFR (mL/min/1.73 m2) 
Albuminuria (mg/g) 
<30 >30 
1 Normal or increased GFR ≥90 
87.9% 
3.7% 
2 Mild decrease in GFR 60-89 3.4% 
3 Moderate decrease in GFR 30-59 4.7% 
4 Severe decrease in GFR 15-29 0.2% 
5 Kidney failure <15 (or dialysis) 0.0% 
 
Table 1. Stages of chronic kidney disease (CKD) and prevalence in the US population. CKD is 
defined as either kidney damage (usually quantified by albuminuria) or glomerular filtration rate (GFR) <60 
mL/min/1.73 m2 for more than three months. Adapted from the revised KDIGO Guidelines65. 
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1.2.2 Chronic kidney disease – mineral and bone disorder 
1.2.2.1 Disturbances in mineral metabolism 
As renal function declines there is a progressive derangement in mineral homeostasis. 
FGF23 increases in early stages of CKD and its rise precedes the reduction in 
1,25(OH)2D and elevation in PTH70,71. Initially, adaptive mechanisms compensate for 
the reduced number of nephrons and maintain serum calcium and phosphate within 
normal ranges. However, starting at CKD stage 3-4 the response to FGF23 and PTH is 
insufficient to compensate for the loss of GFR and phosphate retention and 
hypocalcemia begin to develop72.  
 
Along with the new insights into the dysregulation of mineral metabolism in CKD-
MBD, the sequence of events has been redefined as; increased FGF23 – 1,25(OH)2D-
deficiency – sHPT – hyperphosphatemia. The temporal changes in mineral metabolism 
during CKD progression are summarized in Figure 3. 
 
 
 
 
Figure 3. Temporal changes in mineral metabolism during development of chronic kidney disease-
mineral and bone disorder (CKD-MBD). The rise in fibroblast growth factor-23 (FGF23) is an early event 
during CKD progression, and prevents hyperphosphatemia at the expense of decreased levels of 1,25 
dihydroxyvitamin D (1,25(OH)2D) and a subsequent development of secondary hyperparathyroidism. The 
markedly reduced tissue concentration of the FGF23 co-receptor Klotho in late stages of CKD induces 
end-organ resistance, and FGF23 levels rise exponentially. Adapted from Wolf M72. 
 
 
1.2.2.2 Renal osteodystrophy 
The bone, as one of the main organs for handling calcium and phosphate, is dependent 
on a well-regulated mineral metabolism to maintain its normal function, and as a 
consequence bone abnormalities are frequently found in the CKD population. The 
alterations in bone morphology associated with CKD are termed renal osteodystrophy, 
and encompasses changes in bone turnover, mineralization and bone volume. Renal 
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osteodystrophy may result in fractures, bone pain and impaired linear growth in 
children73. 
 
1.2.2.3 Vascular calcification 
In parallel with bone abnormalities there is an increase in extraosseous calcifications in 
CKD, most importantly in the vasculature. Vascular calcification develops as a result of 
an imbalance between inducers and inhibitors of the calcification process, and several 
known inhibitors, including Fetuin-A and matrix Gla-protein, are reduced in CKD 
patients74,75. Accordingly, vascular calcification is a major concern in CKD patients 
with increased prevalence already at CKD stage 3 (40% compared to 13% in healthy 
individuals), and is a universal phenomenon in ESRD (approximately 80%). Vascular 
calcification is closely related to and considered to be a valid surrogate for the 
longitudinal risk of CVD and mortality76. Although the molecular mechanism behind 
vascular calcification is not fully elucidated it appears to be a combination of passive 
deposition and an active cellular process. The passive deposition is caused by 
precipitation of high circulating concentrations of calcium and phosphate into the 
vascular wall, while the active process is commonly viewed as a dedifferentiation of 
vascular cells into bone-like cells, triggered by various stimuli77. 
 
1.2.2.4 Chronic kidney disease-mineral and bone disorder 
Numerous epidemiological studies have shown a strong correlation between CKD-
related disturbances in mineral metabolism to bone abnormalities, CVD and overall 
mortality3,78. This constellation of features is collectively referred to as chronic kidney 
disease-mineral and bone disorder (CKD-MBD) and defined by one or a combination 
of a) abnormalities in calcium, phosphate, PTH and vitamin D metabolism, b) 
abnormalities in bone metabolism, and c) vascular or other soft tissue calcifications 
(Figure 4)79.  
 
1.2.2.5 Treatment of CKD-MBD 
Current treatment strategies in CKD-MBD are primarily aimed at correcting the 
aforementioned biochemical abnormalities to limit their assumed negative impact on 
clinical outcome. To this end, hyperphosphatemic patients in advanced stages of CKD 
are recommended to receive phosphate-binding agents to reduce the oral phosphate 
load and achieve a neutral phosphate balance. Further, dialysis patients with sHPT 
despite adequate supplementation of calcium and/or vitamin D commonly receive 
treatment with vitamin D analogues or calcimimetics to reduce PTH. However, there 
are to date no large randomized clinical trials (RCTs) that have demonstrated benefit of 
such treatment in terms of hard clinical endpoint (i.e. CVD or mortality)79.  
 
 
  13 
 
 
Figure 4. Development of chronic kidney disease-mineral and bone disorder (CKD-MBD). When 
renal function declines there is a progressive derangement in mineral homeostasis. FGF23 increases in 
early stages of CKD and is followed by 1,25(OH)2D deficiency, hyperphosphatemia and a rise in PTH 
(secondary hyperparathyroidism (sHPT)). The alterations in mineral metabolism is closely linked to renal 
osteodystrophy, ectopic calcification and mortality. 
 
 
1.2.3 FGF23 in CKD 
1.2.3.1 Regulation of FGF23 in CKD 
Phosphate retention due to decreased renal clearance was long considered as the main 
trigger for the increase in FGF23 accompanying CKD progression. Emerging evidence, 
however, emphasize the importance of other factors in initiating and sustaining the high 
FGF23 expression during CKD. Although additional factors likely remains to be 
identified, iron deficiency, vitamin D supplementation, high PTH and hypocalcemia 
have all been implicated in the regulation of FGF23 in CKD35.  
 
1.2.3.2 FGF23 as a predictor of adverse outcome 
In 2008 the first prospective study of FGF23 provided evidence for a graded relation 
between circulating FGF23 and mortality in hemodialysis patients80. The association 
was independent of other established risk factors, and FGF23 had stronger predictive 
value than serum phosphate. This was followed by a number of epidemiological studies 
supporting that FGF23 is associated with adverse clinical outcomes, most importantly 
cardiovascular morbidity, mortality and CKD progression rate, in diverse populations 
1,25(OH)2D ↓ Phosphate ↑
Calcium ↓
Systemic toxicity
Vascular calcification
Cardiovascular disease
Mortality
Renal osteodystrophy sHPT
PTH ↑
Renal failure
FGF23 ↑
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ranging from healthy individuals to various strata of CKD patients and renal transplant 
recipients81-90.  
 
 
1.2.4 Klotho in CKD 
1.2.4.1 Reduced tissue expression of Klotho in CKD 
Many features of aging, such as osteoporosis, oxidative stress, insulin resistance, 
infertility and cognitive dysfunction also characterize the phenotype of renal failure, 
and CKD has accordingly been proposed as a clinical model of premature ageing91. 
Notably, dialysis patients share many biochemical and histological features with 
Klotho-/- mice, with hyperphosphatemia, elevated FGF23 levels, bone abnormalities, 
vascular calcification and reduced survival. Thus, Klotho deficiency could be a 
functional link between Klotho-/- mice and CKD patients explaining their senescent 
phenotype. Due to its tissue residing properties invasive methods are required to 
quantify mKL, which have effectively limited the number of studies available in 
humans. One study using renal biopsies reported on a gradual decrease in mKL as renal 
function decline, with the most severe reduction in patients with diabetic 
nephropathy92. In another study comprising patients with ESRD that had undergone 
nephrectomy, both renal mRNA and protein levels of mKL were nearly undetectable93. 
A large number of animal studies unequivocally confirm the marked reduction of renal 
mKL in renal failure64. Collectively, these data support the concept of CKD as a state 
of Klotho deficiency. 
 
1.2.4.2 Soluble Klotho in CKD 
The relation between soluble Klotho (cKL and sKL) and mKL in CKD is of definite 
interest, but the measurement of soluble Klotho yet suffers from methodological 
shortcomings as previously discussed. In some minor cohort studies using a 
commercially available ELISA, it was reported that soluble Klotho decline in parallel 
with the progression of CKD, although the associations were rather weak94-96. 
Conversely, in a larger study by Seiler et al, soluble Klotho was not associated with 
renal function and in contrast to FGF23 it did not predict adverse outcome in patients 
with CKD stage 2-497. Using a different approach, Hu et al assessed cKL in humans 
and rodents by immunoprecipitation and immunoblotting, and found a marked 
downregulation of serum and urinary cKL as early as in CKD stage 1 and 2, 
presumably reflecting the renal tissue concentration98. In sum, there are conflicting data 
on the levels of soluble Klotho in CKD and additional studies are warranted. 
 
1.2.4.3 Regulation of Klotho in CKD 
The mechanism(s) behind reduced Klotho expression in CKD are not fully understood, 
but are likely to be multifactorial. Several factors associated with CKD, such as RAAS 
activation, oxidative stress, increased levels of tumor necrosis factor and interferon-γ, 
have been shown to decrease Klotho expression in cell culture64. The regulation is rapid 
since also acute kidney injury (AKI) potently decreases renal and circulating 
concentrations of Klotho 
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2 AIMS 
The overall aim of this thesis was to further enhance the understanding of renal and 
parathyroid FGF23-Klotho function in health and disease. Specifically, our objectives 
were: 
 
• To define the role of parathyroid FGF23-Klotho signalling in physiology and in 
the development of renal secondary hyperparathyroidism (Study I and II). 
 
• To investigate the regulation of parathyroid Klotho by factors involved in 
mineral metabolism (Study I).  
 
• To develop a novel, non-surgical model of renal failure in mouse (Study III). 
 
• To explore the function of distal tubular Klotho in renal phosphate handling, 
and its putative role in the regulation of FGF23 (Study IV).  
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 ETHICAL APPROVAL 
All studies in this thesis adhere to the declaration of Helsinki and/or the 3 Rs principle 
(replacement, reduction, refinement), for human and animal studies respectively. Study 
I was approved by the institutional ethical committee at Uppsala University, and 
written informed consent was obtained from all study participants prior to inclusion in 
the study. Study II-IV were conducted in compliance with the guidelines of animal 
experiments of Karolinska Institutet and approved by a regional ethical committee. 
Ethical approval numbers are Uppsala University 00-128 (Study I) and Stockholm 
South ethical committee S38-09, S68-10, S184-10, S118-12 and S19-13 (Study II-IV). 
  
 
3.2 STUDY PARTICIPANTS 
All patients (n=31) included in Study I had undergone surgical parathyroidectomy 
between 1998 and 2008. The study was performed on stored material thus eliminating 
the need for additional interventions. Inclusion criteria were GFR <90 ml/min/1.73 m2 
and access to at least one frozen parathyroid tissue sample. 21 patients were kidney 
transplant recipients, and had undergone transplantation at least one year prior to the 
parathyroidectomy. Parathyroid tissue samples obtained from parathyroid glands 
unintentionally removed during thyroid surgery served as controls. Serum 
biochemistries were measured at the Department of Clinical Chemistry, Uppsala 
University Hospital.  
  
 
3.3 CRE-LOX RECOMBINATION 
Cre-Lox recombination is an efficient and widely used technology to generate tissue-
specific and conditional knockout mice and reporter strains. The mechanism was first 
identified in bacteriophages that use Cre-Lox recombination to circularize and facilitate 
replication of its genomic DNA. It is based on two components: 1) Cre recombinase, a 
site-specific DNA recombinase, and 2) LoxP sites, specific 34 base pair sequences 
allowing for recombination. Neither Cre recombinase nor LoxP sites are native to the 
mouse genome and must be introduced by transgenic techniques. When LoxP sites are 
inserted into the genome, recombination occurs between the LoxP sites in cells 
expressing Cre recombinase, resulting in deletion of a specific DNA sequence or gene 
(Figure 5A). There are also inducible Cre strains available, allowing for studies of age 
dependent gene functions. A drawback of the Cre-Lox system is the variable potency of 
the promoters driving Cre recombination, commonly resulting in less efficient gene 
deletion compared to conventional knockout techniques. Another potential problem is 
the specificity of the Cre promoter, and it is therefore recommended to use reporter 
strains to confirm that Cre expression is restricted to the target tissue99. 
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Figure 5. Cre-Lox recombination as a system for tissue-specific gene deletion. A) Mice expressing 
Cre recombinase under a tissue-specific promotor is crossed with floxed mice to generate targeted 
knockout mice. B) Schematic representation of the wild-type Klotho allele (top), targeting vector (middle), 
and floxed allele with deleted Neo cassette (bottom). LoxP sites are flanking exon 2 of the Klotho gene 
enabling targeted deletion by Cre-Lox recombination. Adapted from Olauson H et al100. 
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Since Klotho-/- mice display extensive morphological abnormalities and dysregulated 
mineral metabolism, we decided to generate floxed Klotho mice to enable dissection of 
tissue-specific effects of Klotho in a more physiological setting. Hence, in Study II and 
IV we use mice with LoxP sequences introduced in the flanking regions of exon 2 of 
the Klotho gene, resulting in disrupted gene function in tissues expressing Cre 
recombinase (Figure 5B). Briefly, the sequence of mouse chromosome 5 was retrieved 
from the Ensembl database (http://www.ensembl.org). The RP23-434H9 BAC clone 
was used for generation of homology arms and the conditional knockout region of the 
targeting vector. The fragments were cloned in the LoxFtNwCD or pCR4.0 vector and 
electroporated into C57BL/6 embryonic stem cells. Male chimeras were generated and 
subsequently bred with wild-type females to generate Klotho-LoxP heterozygotes 
(Klothoflox/+). Floxed Klotho mice were crossed with mice expressing Cre recombinase 
under different promotors, to achieve tissue-specific deletion of Klotho. In Study II we 
used mice expressing Cre recombinase under the human PTH promotor (129;FVB-
Tg(PTH-cre)4167Slib/J; Jackson laboratory, ME, US)101 to generate parathyroid-
specific Klotho knockout mice. In Study IV we used mice expressing Cre recombinase 
under the Ksp-cadherin promoter (B6.Cg-Tg(Cdh16-cre)91Igr/J; Jackson laboratory, 
ME, US)102, to generate mice with a distal tubule-specific deletion of Klotho. In both 
studies homozygous mice without Cre (Klothoflox/flox) served as wild-type controls. In 
Study IV, mice with a systemic Klotho deletion were generated using mice expressing 
Cre under the human beta-actin promotor (FVB/N-Tg(ACTB-cre)2Mrt/J, Jackson 
laboratory). All Cre strains had previously been crossed to reporter mice to verify tissue 
specificity of Cre expression. Mice with a C57BL/6 background were used for 
maintenance breeding. 
 
 
3.4 TRANSCRIPT ANALYSIS 
Quantitative real time PCR (qPCR) is a common and sensitive method to amplify and 
quantify specific gene products. The method can use either DNA binding dyes such as 
SYBR Green, or sequence specific fluorescent reporter probes. In this thesis, total RNA 
was extracted and reverse-transcribed into cDNA, and qPCR subsequently performed 
using gene-specific primers in SYBR Green based assays, except otherwise stated. The 
relative gene expression was calculated with the 2-ΔΔ Cq or Ct method normalizing the 
gene of interest to the reference genes GAPDH (Study I) or β-actin (Study II-IV) in the 
same sample. 
 In Study II mouse parathyroid tissue was microdissected using laser 
capture microscopy and mRNA expression profiles were obtained with the nanostring 
nCounter system (Nanostring technologies, Inc.). Nanostring uses confocal microscopy 
to count fluorescently bar-coded probes, detecting and quantitating RNA molecules 
without amplification or introduction of position-dependent effects. Data were 
processed using different normalization strategies, including quantile normalization and 
six reference genes. 
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3.5 IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE 
Immunohistochemistry (IHC) and immunofluorescence (IF) utilize antibodies for 
detection of specific target antigens. The techniques are widely used in both scientific 
research and clinical practice. Adequate preparation of the tissue sample is crucial to 
maintain tissue morphology and antigenicity of the target epitopes. After fixation and 
sectioning additional steps, including antigen retrieval, may be necessary to allow the 
antibody to bind its epitope.  The antibodies used for IHC and IF may be monoclonal or 
polyclonal. Polyclonal antibodies are a mix of antibodies recognizing several different 
epitopes, whereas monoclonal antibodies bind a single epitope and are therefore 
considered to be more specific. Further, antibodies are classified into primary and 
secondary antibodies. Primary antibodies are raised against the epitopes of interest, and 
secondary antibodies target immunoglobulins on the primary antibodies, and are 
usually conjugated with a linker molecule or directly bound to a reporter molecule. The 
reporter molecules differs between IHC and IF. While IHC uses chromogenic reporters 
yielding a colour that can be seen with a regular light microscope, IF uses fluorophores 
requiring a fluorescence microscope for detection. The different wavelength of the 
fluorophores permits simultaneous staining with several different antibodies in IF.  
IHC and IF are excellent techniques for protein detection and can show 
precisely where a specific protein is located within the tissue sample, or even the 
subcellular location within a single cell. Main drawbacks of IHC and IF is the risk for 
unspecific staining and that they only provide a semi-quantitative assessment of protein 
expression. 
The specificity of all antibodies used for IHC or IF in this thesis was 
verified by immunoblot or other techniques. IHC and IF techniques were primarily 
used to investigate the expression pattern and/or localization of specific proteins, and 
secondarily for semi-quantification when transcript analysis or immunoblotting were 
not available.  
 
 
3.6 STATISTICAL ANALYSIS 
GraphPad Prism version 5.0 or higher (GraphPad Software Inc, CA, US) was used for 
statistical analysis. Biochemistries in Study I are presented as means ± SD. Non-
normally distributed parameters were logarithmized before analysis. In Study II-IV data 
is presented as arithmetic means ± SEM or median (range), unless otherwise stated. 
Gaussian distribution was tested using D’Agostino and Pearson omnibus normality test. 
Variables fulfilling the criteria for normal distribution were compared with two-tailed 
unpaired t-test. Treatment results were evaluated using paired t-test. Non-normally 
distributed variables were compared using Mann-Whitney test. Correlations between 
variables were tested with Pearson or Spearman correlation test. P-values <0.05 were 
considered statistically significant. 
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4 RESULTS AND DISCUSSION 
4.1 PARATHYROID KLOTHO AND FGFR1 DECLINE IN PARALLEL WITH 
RENAL FUNCTION IN CKD PATIENTS WITH SECONDARY 
HYPERPARATHYROIDISM (STUDY I) 
The concomitant increase in FGF23 and PTH during CKD progression is a paradoxical 
phenomenon, given that FGF23 was shown to inhibit PTH synthesis and secretion. 
Study I was designed as an exploratory study to test the hypotheses of parathyroid 
FGF23 resistance in CKD due to downregulation of the responsible receptors. To this 
end, we investigated the transcript and protein expression of Klotho and FGFR1 in 88 
parathyroid glands from 31 patients with CKD and sHPT103. Overall, parathyroid 
Klotho and FGFR1 levels were markedly decreased in patients with sHPT, although 
there was a large intraglandular variation. Mean Klotho levels correlated positively to 
renal function (r=0.42; p<0.05), and declined significantly over CKD stages (Figure 6). 
Also parathyroid FGFR1 correlated to renal function (r=0.50; p<0.01) and accordingly 
decreased across CKD stages. Serum phosphate but not calcium or PTH associated to 
Klotho levels, whereas phosphate and PTH correlated negatively to FGFR1 expression. 
Unfortunately, lack of serum prevented us from determining FGF23 and 1,25(OH)2D 
levels. 
 
 
 
Figure 6. Parathyroid Klotho expression declined over chronic kidney disease (CKD) stages. CKD 
3 was set as reference. ***p<0.001 versus reference. Error bars represent the 5th and 95th percentiles. 
Outliers are represented by dots. 
 
To further explore the regulation of parathyroid Klotho we performed in vitro 
experiments using isolated bovine parathyroid cells. As previously shown, calcium 
potently suppress Klotho expression at 24 hours104. Likewise, treatment with 
recombinant FGF23 at physiological concentrations decreased the expression of 
Klotho. Conversely, treatment with 1,25(OH)2D or a vitamin D analogue (EB1089) 
dose-dependently increased Klotho expression. There was no effect on Klotho levels by 
treatment with phosphate or PTH. Co-treatment with EB1089 could not mitigate the 
suppressive effects of FGF23 or calcium on Klotho expression (Figure 7). All treatment 
effects were blunted in human hyperplastic parathyroid cell culture. 
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 The downregulation of parathyroid FGFR1-Klotho receptor complex 
seen in patients with impaired renal function and sHPT corroborates the hypothesis of 
FGF23 parathyroid resistance in CKD. Other groups have also presented similar 
results105,106. In further support of this notion, rats with adenine-induced renal failure 
had decreased parathyroid expression of Klotho and FGFR1, and treatment with FGF23 
failed to inhibit PTH secretion107. 
 
 
 
 
Figure 7. Klotho regulation by calcium (Ca), vitamin D analogue (VDA), and fibroblast growth 
factor-23 (FGF23) in cultured bovine parathyroid cells. Calcium and FGF23 treatment decreased 
Klotho expression at 24 h, whereas treatment with the vitamin D analogue EB1089 increased Klotho 
mRNA levels. Co-treatment with EB1089 did not attenuate the suppressive effects of FGF23 or calcium on 
Klotho expression. The concentrations used were 4 mmol/l calcium, 2000 pg/ml FGF23, and 10-7 mol/l 
EB1089. Data is presented as median ± SEM. N=2-4. Ctrl; control medium. **p<0.01 , ***p<0.001 versus 
control. 
 
Several potential mechanisms underlying the suppression of parathyroid Klotho and 
FGFR1 in CKD can be envisioned. First, it might be attributed to the loss of 
parathyroid cell phenotype as hyperplasia progresses. Second, it could speculatively be 
caused by CKD-related alterations in serum biochemistries, most importantly 
1,25(OH)2D deficiency and FGF23 excess, as supported by our in vitro data. Although 
FGF23 suppresses PTH secretion in the short-term, sustained exposure to high FGF23 
could potentially in the long-term decrease the abundance of the FGFR1-Klotho 
receptor complex. Third, additional circulating and tissue factors associated with the 
progression of renal failure may be implicated. In this regard, uremic toxins have been 
shown to decrease renal Klotho expression in vitro and in vivo through 
hypermethylation of the promoter region108,109. Similarly, we found increased promoter 
methylation paralleling the decreased expression of parathyroid Klotho in hyperplastic 
parathyroid glands (unpublished data).  
Collectively, parathyroid expression of Klotho and FGFR1 declines with 
renal function, and may provide an explanation to the putative parathyroid resistance to 
FGF23 in advanced stages of CKD and sHPT. 
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4.2 GENETIC EVIDENCE FOR A NOVEL, KLOTHO-INDEPENDENT, 
FGF23-SIGNALLING PATHWAY IN THE PARATHYROID GLANDS 
(STUDY II) 
As previously shown, parathyroid resident Klotho mediates FGF23 suppression of PTH 
secretion. Thus, its reduced abundance in CKD might be a pathogenic factor in the 
development of sHPT. To test this hypothesis and to test the physiological role of 
parathyroid Klotho we generated parathyroid-specific Klotho knockout mice (PTH-KL-
/-) using Cre-Lox recombination. Successful deletion of parathyroid Klotho was 
confirmed with immunohistochemical staining (Figure 8) and analysis of mRNA 
transcripts. PTH-KL-/- mice had a normal gross phenotype and unaltered serum PTH 
and calcium levels. Notably, serum levels of 1,25(OH)2D were significantly increased 
in PTH-KL-/- mice compared to wild-type mice. Parathyroid size and histology was 
unchanged in PTH-KL-/- mice and there were no apparent changes in protein expression 
of PTH, CaSR or VDR. Analysis of parathyroid mRNA transcripts for >90 genes 
essential for parathyroid function revealed significant expressional changes for several 
genes, including Cfd (Entrez Gene: 11537), Fabp4 (11770) and Smad4 (17128).  
 
 
 
 
Figure 8. Immunohistochemical staining revealed successful deletion of parathyroid Klotho in 
parathyroid-specific Klotho knockout mice (PTH-KL-/-). Efficiency of deletion varied, and was up to 
>90%. Wild-type (WT) 
 
The parathyroid response to acute alterations in serum calcium did not differ between 
PTH-KL-/- mice and wild-type mice, and PTH-KL-/- mice challenged with renal failure 
developed sHPT of similar magnitude as wild-type mice. Notably, serum FGF23 levels 
increased by approximately 50-fold in mice challenged with renal failure, yet it did not 
suppress PTH secretion neither in PTH-KL-/- nor in wild-type mice. Conversely, 
intravenous FGF23 administration decreased PTH equally in PTH-KL-/- and wild-type 
mice. Importantly, the suppressive effect of FGF23 on PTH secretion was not mediated 
by the MAPK pathway in PTH-KL-/- mice since phosphorylation of ERK1/2 was 
abrogated in Klotho-deficient cells. To identify the pathway responsible for FGF23 
suppression of PTH in PTH-KL-/- mice we examined if the calcineurin/NFAT pathway, 
another major downstream signalling pathway of FGFR activation, was activated. 
Indeed, NFAT2C had a partial nuclear localization in PTH-KL-/- mice contrasting the 
cytoplasmatic localization in wild-type mice, and MCIP1, a facilitator of calcineurin 
activity, was markedly upregulated in PTH-KL-/- mice. To provide in vivo evidence that 
WT PTH-KL-/-
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the calcineurin/NFAT pathway mediated FGF23 actions, PTH-KL-/- and wild-type mice 
were treated with the calcineurin inhibitor cyclosporine A prior to injection of FGF23. 
As shown in Figure 9, pre-treatment with cyclosporine A nearly abolished the 
suppressive effect of FGF23 on PTH secretion in PTH-KL-/- mice, whereas wild-type 
mice remained responsive to FGF23 actions. These observations were confirmed in 
thyroparathyroid explants ex vivo. 
 
 
 
 
 
Figure 9. Parathyroid hormone (PTH) response to a single intravenous injection of fibroblast 
growth factor-23 (FGF23) with and without pretreatment by cyclosporin A (CsA). Wild-type mice 
(WT) pretreated with the calcineurin inhibitor CsA had a preserved responsiveness to FGF23 as 
evidenced by a significant reduction in serum PTH 15 minutes after a single FGF23 injection i.v. In 
contrast, the FGF23-mediated inhibition of serum PTH was blunted in PTH-KL-/- mice pretreated with CsA. 
*p<0.05. 
 
 We conclude that deletion of parathyroid Klotho does not alter the 
sensitivity to acute fluctuations in serum calcium, or aggravates the sHPT in renal 
failure, as previously suggested. This is presumably explained by compensatory 
activation of the calcineurin/NFAT pathway in the absence of Klotho. The 
calcineurin/NFAT pathway has previously been implicated in FGF23 effects on 
cardiomyocytes that lack endogenous Klotho expression, resulting in increased cell 
growth and left ventricular hypertrophy110. Our findings support FGF23 activation of 
the calcineurin/NFAT pathway also in parathyroid glands, a tissue normally expressing 
Klotho. The discovery of Klotho-independent FGF23 signalling in the parathyroid 
glands and heart presents the possibility of FGF23 effects in tissues that so far may 
have been overlooked. This could be particularly relevant in CKD patients who suffer 
from markedly elevated FGF23 levels, which in turn have been independently linked to 
adverse clinical outcomes. Reduced abundance of parathyroid Klotho in CKD is 
currently a generally endorsed concept for parathyroid FGF23 resistance and thus for 
aggravation of sHPT. However, our data clearly demonstrate that the parathyroid 
glands remain responsive to FGF23 despite absence of Klotho, and that parathyroid 
Klotho deficiency does not translate into aggravated sHPT in renal failure. Thus, the 
observed parathyroid FGF23 resistance in CKD is more likely to be attributed to 
reduced FGFR expression.  
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In sum, our data suggest that the calcineurin/NFAT pathway is activated 
by FGF23 in the parathyroid glands of PTH-KL-/- mice to suppress PTH secretion. The 
presence of Klotho-independent effects of FGF23 in a Klotho expressing tissue could 
represent a paradigm shift in the understanding of FGF23 signalling. 
 
 
4.3 A NOVEL, NON-INVASIVE, MODEL OF EXPERIMENTAL RENAL 
FAILURE IN MICE (STUDY III) 
The use of in vivo models of renal failure is essential to study a number of aspects 
related to acute renal injury and CKD. However, most existing models in mice require 
invasive surgical procedures or are based on single injections with nephrotoxic 
substances, thus preventing the possibility to temporally adjust the level of 
uremia111,112. To bypass these limitations we developed a novel, non-invasive, model of 
renal failure through dietary delivery of adenine113. This technique has previously been 
established in rats114, but has not been possible to adapt in mice due to their reluctance 
to consume adenine. We were able to circumvent this problem by mixing the adenine in 
a casein-based diet, masking its repugnant smell and taste. Through a series of pilot 
studies we determined the “optimal” urea range to be between 80 and 100 mg/dL in 
terms of presence of disturbances in mineral metabolism without any mortality. Next 
we performed an eight weeks long proof-of-concept study, comprising an induction 
phase and a maintenance phase. During the 10-day induction phase the adenine 
concentration was set to 0.3%, causing a rapid increase in serum urea, phosphate, PTH 
and FGF23. When the optimal urea range was reached, the adenine concentration was 
lowered to maintain a stable level of renal dysfunction and biochemical disturbances. 
During the maintenance phase the adenine concentration was modified in the interval 
0.15-0.2%. Lowering the dose to 0.15% resulted in a rapid decline in urea, phosphate 
and PTH, suggesting at least partial reversibility of the model. Interestingly, FGF23 
levels increased continuously throughout the entire study, indicating reduced renal 
clearance or that renal injury per se stimulates FGF23 expression. Of note, mice on 
adenine did not have increased proteinuria. This is likely explained by the limited 
glomerular damage in this model, and the known resistance of C57BL/6 mice towards 
developing proteinuria115. Serum markers of bone metabolism were assessed and 
indicated an increased bone formation and a reduced bone resorption.  
Renal histology showed mainly tubulointerstitial damage with peritubular 
leukocyte infiltration and interstitial/peritubular edema. However, in some but not all 
adenine-exposed mice also the glomeruli were affected. Ladewig staining revealed a 
mild interstitial fibrosis, and in von Kossa stain extensive calcification of tubular 
structures was observed. Histological evaluation of the parathyroid glands revealed no 
overt hypertrophy although proliferation rate was markedly increased. Bone analysis 
showed extended bone trabeculae and increased bone marrow adiposity in the femurs, 
corroborating with the serum markers of bone metabolism. No vascular calcification 
was found in the thoracic aortas of adenine-treated mice. 
Further, we analysed the expression of a number of renal genes associated 
with inflammation or fibrosis. Inflammatory markers Mmp3 (Gene ID: 17392), Mmp9 
(17395), Il7rα (16197), Ccl20 (20297) and Ccl5 (20304) were all significantly 
upregulated in adenine-exposed mice. Corresponding markers of fibrosis Tgfb1 
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(21803), Col1a1 (12842) and Ccl2 (20296) were also elevated compared to mice on a 
control diet. 
In sum, we have developed a novel adenine-based protocol to induce 
tubulointerstitial nephropathy in mice mimicking several features of human CKD-
MBD, i.e. disturbances in mineral metabolism and bone abnormalities. One of its main 
advantages is the possibility to adjust the urea levels by altering the adenine 
concentration, thus allowing for adaptive studies in terms of severity of renal failure 
over time. Another major benefit over other common models is that there is no need for 
surgical intervention, making it available also to groups with limited experience of 
surgical techniques. It should be pointed out that there are several advantages of using 
rats instead of mice, including higher tolerance towards adenine and larger blood 
sample volumes. However, since genetically modified strains mainly exist in mice, 
experimental models of renal failure in mice are a requisite to study the impact of 
specific genes in the uremic setting. In that context, our model will serve as an 
important complement to existing models for studies of gene function in the setting of 
renal failure. 
 
 
4.4 PARTIAL DELETION OF DISTAL TUBULAR KLOTHO INCREASES 
FGF23 AND DISRUPTS MINERAL METABOLISM (STUDY IV) 
Renal Klotho is obligate to maintain a normal mineral homeostasis, both through direct 
regulation of calcium- and phosphate-transporters, and by mediating the effects of 
FGF23 on phosphate and vitamin D metabolism. However, the mechanism by which 
FGF23 binds Klotho to increase phosphate wasting is debated. Klotho is predominantly 
expressed in the distal tubule, while phosphate reabsorption occurs in the proximal 
tubule. On one hand it has been reported that there is sufficient Klotho expression in the 
proximal tubule to allow FGF23 signalling116, while on the other hand the initial 
activation of downstream signalling events upon FGF23 administration resides 
exclusively in the distal tubule117. To enhance the understanding of renal FGF23-
Klotho signalling and function, we generated distal tubule-specific Klotho knockout 
mice (Ksp-KL-/-) by crossing floxed Klotho mice with mice expressing Cre-
recombinase under the Ksp-cadherin promoter100. We validated the specificity of the 
Ksp-cadherin promotor by crossing Cre-mice to a reporter strain (unpublished data, see 
cover image). Partial deletion of distal tubular Klotho was confirmed with 
immunohistochemistry (Figure 10), and analysis of renal transcripts revealed that 
residual Klotho expression in Ksp-KL-/- mice varied between 26% and 100%.  
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Figure 10. Immunohistochemical staining revealed partial deletion of distal tubular Klotho in Ksp-
KL-/- mice. Efficiency of deletion varied between 0-74% compared to wild-type mice. WT; wild-type 
 
In contrast to systemic Klotho knockout mice, Ksp-KL-/- mice were viable, fertile and 
had normal longevity. However, Ksp-KL-/- mice were hyperphosphatemic with elevated 
FGF23 levels, corresponding to the degree of residual Klotho expression. PTH was 
decreased whereas calcium and 1,25(OH)2D remained normal. Urinary calcium 
excretion was increased and urinary phosphate excretion unchanged. The increased 
calciuria could speculatively be due to decreased activity of TRPV5, as a downstream 
effect of reduced Klotho. In a subgroup of Ksp-KL-/- mice with normal serum 
phosphate, FGF23 levels were higher than in wild-type mice. This indicates that factors 
other than serum phosphate stimulate FGF23 expression in Ksp-KL-/- mice. Since there 
was a high variability in Klotho expression, we categorized the Ksp-KL-/- mice into 
three groups based on residual expression; >70% (mean Klotho expression 88%, n=7), 
30-79% (59%, n=6) and <30% (28%, n=2). There was a gradual increase in serum 
phosphate and calcium with lower Klotho levels, whereas a threshold was seen for 
FGF23 with extremely elevated levels when renal Klotho was <30% (Figure 11). 
 
 
 
 
Figure 11. Serum phosphate and fibroblast growth factor-23 (FGF23) levels in wild-type and Ksp-
KL-/- mice categorized according to residual Klotho expression. There was a gradual decline in serum 
phosphate with lower Klotho expression, whereas a threshold was seen for FGF23, with a marked 
elevation when Klotho was <30%. WT; wild-type 
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No major differences were found in renal or parathyroid histology between wild-type 
and Ksp-KL-/- mice. To determine the impact of Klotho deletion on key factors 
regulating mineral metabolism, we examined renal protein and transcript expression. 
Immunostaining revealed increased abundance of the sodium phosphate co-transporter 
Npt2a on the apical membrane, in concordance with the observed hyperphosphatemia 
in Ksp-KL-/- mice. Immunoblotting showed increased renal levels of VDR and 
decreased levels of TRPV5 in Ksp-KL-/- mice. Transcript levels of renal Cyp27B1 were 
increased in Ksp-KL-/- mice, and Klotho transcripts correlated to Cyp27B1, VDR, 
Npt2a, and FGFR1.  
Collectively, we present genetic and functional evidence that partial 
deletion of Klotho in the distal tubules has a major impact on renal phosphate handling 
in the proximal tubules. The factor(s) responsible for this proposed distal-to-proximal 
tubule signalling are currently unknown, but could speculatively be soluble Klotho 
shedded from the cell surface upon binding of FGF23. Although distal tubular Klotho 
appears essential to renal phosphate handling, our results indicate a limited effect on 
vitamin D metabolism. Importantly, our data does not exclude a role for Klotho in the 
proximal tubule, and this should be further examined in future studies. 
The variable efficiency of deletion allowed us to study dose-dependent 
effects of Klotho on mineral metabolism. Indeed, we found a graded relationship 
between residual Klotho expression and serum phosphate, calcium and PTH. 
Conversely, serum FGF23 increased exponentially when Klotho expression was below 
30%. This could represent a compensatory response due to renal FGF23 resistance. In 
support, the Ksp-KL-/- mice with the most efficient Klotho deletion displayed 
pronounced hyperphosphatemia in the face of markedly elevated FGF23 levels.  
The elevated FGF23 raises another important question; how does reduced 
renal Klotho translate into increased expression of FGF23 in bone? Secondary 
mediators such as hyperphosphatemia are likely to account for part of the increase. 
However, also in in Ksp-KL-/- mice with normal phosphate levels, FGF23 levels was 
elevated, implying that additional factors are involved. Again, soluble Klotho acting on 
the bone is a plausible factor. Further studies are needed to explore this potential 
relationship.   
 In stark contrast to Klotho-/- mice, Ksp-KL-/- mice are viable and fertile 
with an essentially normal gross phenotype. This contradicts that Klotho deficiency per 
se causes systemic toxicity. However, the knockout is incomplete and the residual 
Klotho might be sufficient to maintain a normal phenotype. Similarly, the lack of renal 
fibrosis and vascular calcification argues against direct paracrine effects of Klotho on 
maintaining cellular integrity, at least during low cellular stress. These characteristics 
might be more pronounced in Ksp-KL-/- mice with ageing or by induction of renal 
failure, and should be tested in subsequent studies.  
 
A summary of the phenotypes seen in various models of Klotho deficiency is found in 
Table 2. 
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Parameter Klotho-/- mice PTH-KL-/- mice Ksp-KL-/- mice CKD 
Blood chemistry     
Phosphate ↑↑↑ Normal ↑ ↑-↑↑ 
GFR ↑ Normal Normal ↓-↓↓↓ 
FGF23 ↑↑↑ Normal ↑-↑↑ ↑-↑↑↑ 
PTH ↓↓ Normal ↓ ↑-↑↑ 
Renal Klotho 0 Normal ↓-↓↓ ↓-↓↓↓ 
Parathyroid Klotho 0 ↓↓↓ Normal ↓↓ 
Soluble Klotho 0 Normal? ↓-↓↓? ↓-↓↓↓? 
Gross phenotype     
Body weight ↓↓ Normal/↓ Normal ↓ 
Growth ↓↓ Normal Normal ↓ (in children) 
Physical activity ↓↓ Normal Normal ↓ 
Fertility 0 Normal Normal ↓ 
Life span ↓↓ Normal Normal ↓↓ 
Cardiovascular 
disease 
    
Heart 
Hypertrophy and 
fibrosis 
Normal Normal 
Hypertrophy and 
fibrosis 
Vasculature Calcification Normal Normal Calcification 
Blood pressure ↑ ? ? ↑↑ 
Anemia Mild ? ? Severe 
Bone 
Osteomalacia/ 
Osteoporosis 
Normal Normal 
Renal bone 
disease 
 
Table 2. Characteristics of various states of Klotho deficiency. Systemic Klotho knockout mice 
(Klotho-/-), parathyroid-specific Klotho knockout mice (PTH-KL-/-), distal tubule-specific Klotho knockout 
mice (Ksp-KL-/-) and chronic kidney disease (CKD). Pathological parameters are described as absent (0), 
mild (↓/↑), severe (↓↓/↑↑) or extreme (↓↓↓/↑↑↑). In part adapted from Hu MC et al64.  
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5 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
The identification of FGF23 (2000) and Klotho (1997) represents a paradigm shift in 
the conceptualization of mineral metabolism in health and disease. Despite major 
advances over the last decade there are still fundamental gaps in the understanding of 
the regulation and function of this endocrine axis.  
 
5.1 NOVEL FINDINGS AND IMPLICATIONS 
The studies presented in this thesis contribute substantially to the knowledge of FGF23-
Klotho function and regulation, both in physiology and in CKD. We provide evidence 
that parathyroid Klotho and FGFR1 declines in parallel with decreased GFR in patients 
with CKD and sHPT; that reduced Klotho level can be directly mediated by 
hypercalcemia, vitamin D deficiency and elevated FGF23; and that suppression of the 
FGFR1-Klotho receptor complex may provide the functional basis for parathyroid 
FGF23 resistance in CKD. To further define the role of parathyroid Klotho we 
generated parathyroid-specific Klotho knockout mice. Contradictory to the current 
paradigm, parathyroid Klotho ablation does not impact the calcium sensitivity or 
aggravate renal uremic sHPT. Further, despite absence of Klotho and loss of functional 
MAPK signalling the parathyroid glands retain FGF23 responsiveness. On these 
premises, we identified a novel, calcineurin-dependent, pathway that mediates the 
suppressive effects of FGF23 on PTH secretion. The existence of a Klotho-independent 
FGF23 signalling pathway in a Klotho-expressing organ represents a paradigm shift in 
the conceptual framework of FGF23 endocrine function. Speculatively, high FGF23 
may negatively impact clinical outcomes in CKD through enhanced calcineurin 
signalling. Other implications include the possibility of iatrogenic FGF23 resistance 
and aggravation of sHPT after kidney transplantation when serum FGF23 remains 
elevated in conjunction with the use of calcineurin inhibitors as immunosuppressive 
therapy.  
To allow studies of specific gene function and pharmacological intervention in a 
uremic milieu, we developed a novel non-surgical mouse model of renal failure by 
adding adenine to the diet. Mice exposed to adenine developed tubulointerstitial lesions 
and secondary changes in bone and mineral metabolism, resembling human CKD-
MBD. Adenine-induced renal failure thus constitutes a novel and useful tool for studies 
of genetic and pharmacological manipulations in CKD-MBD.  
Furthermore, by generating mice with a distal tubule-specific deletion of Klotho 
we provide in vivo evidence for a vital and dose-dependent role of distal tubular Klotho 
on renal phosphate handling in the proximal tubule. This supports the presence of a 
distal-to-proximal tubule signalling mechanism. Elevated levels of FGF23 despite 
normal serum phosphate in mice with a partial deletion of renal Klotho also suggest 
that renal derived factors such as soluble Klotho may directly regulate FGF23 
expression in bone. Finally, the lack of fibrosis, calcification or other age-related 
histological abnormalities in Klotho-deleted cells argues against a direct role for Klotho 
in regulation of cellular senescence. 
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5.2 LIMITATIONS  
Several limitations in the work of this thesis should be mentioned. Study I is largely 
exploratory with regard to Klotho and FGFR1 analysis in human tissue specimen. 
External factors such as age, co-morbidities, medication, renal replacement therapy etc. 
are likely to influence Klotho and FGFR1 levels. Importantly, a majority of the patients 
were renal transplant recipients and on immunosuppressive therapy, which may impact 
the expression of parathyroid Klotho and FGFR1. However, the patient sample was too 
small to perform a robust sensitivity analysis. Also, lack of serum prevented us from 
analysing FGF23 and 1,25(OH)2D, which would have been enlightening given that 
they directly regulate Klotho expression in bovine parathyroid cells. Consequently, 
some results from our regression models should be interpreted with caution due to 
residual confounding factors.  
In Study II and IV, the impact of tissue-specific Klotho deletion was examined in 
mice. Although endocrine regulation of mineral metabolism is a highly preserved 
system across mammal species, results derived from animal studies cannot be 
translated into humans without careful consideration. Yet, mice have been valuable in 
previous studies in terms of predicting human FGF23-Klotho physiology. Also some 
potential methodological shortcomings deserve mentioning. The efficiency of Klotho 
deletion in Study II and IV varied, and was incomplete. To partially overcome this 
problem we performed subgroup analysis comparing animals with different degrees of 
deletion. Nevertheless, we cannot rule out that a complete deletion of Klotho in the 
specific tissue would have yielded different results.  
In Study III, the underlying aetiology of adenine-induced nephropathy is tubular 
toxicity, which contrasts human CKD where the most common pathology is glomerular 
scarring. Thus, this model should not be regarded as a model of CKD-MBD per se but 
rather as model of tubulointerstitial disease. Adenine may also have extra-renal effects 
that modify the phenotype independently of uremia. Further, we did not examine 
reversibility of renal failure or long-term impact of adenine administration. 
 
 
5.3 GENERAL DISCUSSION 
5.3.1 PTH regulation 
The calcium-PTH sigmoidal curve defines that relatively small changes in systemic 
calcium ion concentrations evoke large responses in PTH secretion. This is regulated 
through activation or inactivation of CaSR expressed at the surface of parathyroid chief 
cells. In addition to calcium, several other components of mineral metabolism regulate 
PTH synthesis and secretion. Local VDR activation inhibits PTH release whereas high 
phosphate promotes PTH secretion and parathyroid gland hyperplasia. sHPT is a 
universal feature of CKD patients and has traditionally been attributed to the triad of 
1,25(OH)2D deficiency, hypocalcemia and hyperphosphatemia118. The discovery of 
FGF23 and Klotho has prompted a re-evaluation of parathyroid physiology and sHPT 
pathophysiology. In physiology, FGF23-Klotho signalling inhibits PTH secretion 
whereas Klotho was reported to mediate PTH secretion during hypocalcemia. However 
our studies contradict that Klotho is essential for PTH secretion during hypocalcemia, 
at least in the short-term. Further, we provide evidence that Klotho is not critical for 
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FGF23 suppression of PTH since calcineurin-NFAT signalling can mediate the same 
effects in the absence of Klotho. Similar “rescue pathways” are also seen for other vital 
biological systems, and its existence emphasizes the importance of fine-tuning systems 
for maintaining calcium homeostasis. This leaves us with the questions what the true 
function of parathyroid Klotho is, and to what extent parathyroid FGF23 signalling is 
relevant in physiology. We propose that FGF23, in analogue with 1,25(OH)2D, has a 
fine-tuning role subordinate to CaSR in the regulation of PTH secretion. The proposed 
endocrine regulation of PTH in physiology is depicted in Figure 12. In sHPT the 
situation might be somewhat different. The parallel rise in FGF23 and PTH was 
initially perceived as an enigma assuming a negative feedback from FGF23 on PTH 
secretion. There are however several plausible explanations for this observation. In 
advanced sHPT, the parathyroid glands are unresponsive to FGF23 signalling, and our 
data support that this is due to suppression of FGFR rather than loss of Klotho. At early 
and intermediate stages of sHPT FGF23 likely has an inhibitory effect on PTH, but that 
may be overshadowed by the FGF23-mediated decrease in systemic 1,25(OH)2D 
levels. This is supported by studies showing improved biochemical profile, including 
higher 1,25(OH)2D and lower PTH levels, in uremic rats treated with FGF23 
neutralizing antibodies119. The dominant role of 1,25(OH)2D deficiency over FGF23 
excess on PTH regulation is further evidenced by the high PTH and parathyroid gland 
hyperplasia in transgenic mice overexpressing FGF2331. 
 
 
 
 
 
Figure 12. Proposed regulation of parathyroid hormone (PTH) by vitamin D, calcium and fibroblast 
growth factor-23 (FGF23) in physiology. Active vitamin D (1,25(OH)2D) acts on the nuclear vitamin D 
receptor (VDR) to inhibit PTH synthesis. Activation of the calcium sensing receptor (CaSR) by high serum 
calcium also suppresses PTH secretion. Conversely, low serum calcium inactivates CaSR and facilitates 
PTH release. FGF23 has been shown to suppress PTH synthesis and secretion, through both Klotho-
dependent and -independent pathways. 
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5.3.2 Regulation of FGF23 in CKD 
Although an extensive amount of epidemiological and in vivo data convincingly argues 
that increased FGF23 is an early and sensitive biomarker of renal damage, some 
fundamental questions need to be answered before measurement of FGF23 can be 
applied in the clinical practice. First, there is some controversy on the processing of 
FGF23 in CKD. While some report on accumulation of c-terminal fragments in 
ESRD120, others found almost exclusively intact bioactive FGF23 in dialysis patients121. 
Another central issue is how and why the increase in FGF23 expression is initiated. 
Phosphate retention due to decreased renal clearance was initially believed to be the 
main trigger for FGF23 in CKD. However, clinical data suggest a biphasic profile in 
serum phosphate in CKD that begins with a hypophosphatemic phase, arguing against 
hyperphosphatemia as the principal stimuli of FGF23 in early CKD71. In support, in a 
recent study dietary phosphate restrictions alone could not prevent the rise in FGF23 in 
a mouse model of progressive CKD122. Another study showed a marked increase in 
FGF23 within hours after induction of acute kidney injury (AKI), independent of 
dietary phosphate123. Further, treatment with phosphate-binding agents in patients with 
CKD stage 3-4 reduces the levels of serum phosphate, but do not normalize 
FGF23124,125. In a recent review, Kuro-o presents the intriguing hypothesis that the 
elevated FGF23 in early CKD reflects an increased phosphate load per nephron, rather 
than high serum phosphate126. Recent studies also promote expressional changes in 
DMP1, PHEX and Sclerostin as intrinsic regulators of FGF23 expression in CKD127. 
Other newly identified regulators of FGF23 in bone include FAM20C and Entpd5, 
which when deleted in mice reduces mineralization of bone and stimulates FGF23 
synthesis128,129. Additional upstream factors such as local FGFR activation, inorganic 
polyphosphates, sex steroids, retinols and osteoprotegerin have also been implied. It is 
plausible that also the failing kidney itself promotes FGF23 expression, either by 
secreting a stimulating factor or by reduced production of an inhibitor. Indeed, as 
supported by the findings in this thesis, renal but not parathyroid Klotho deficiency per 
se appears to induce FGF23 expression. Finally, accumulation due to decreased urinary 
clearance of FGF23 in CKD has been proposed as a possibility, but is unlikely to be a 
major determinant according to a recent study123. Taken together, it appears unlikely 
that one single factor will be identified as responsible for the increased FGF23 
expression in CKD, but rather that numerous factors are involved in a complex 
interplay.  
 
 
5.3.3 Regulation of Klotho in CKD 
Downregulation of Klotho in CKD appears to be equally multifaceted as the increase in 
FGF23. In addition to reduced renal mass, numerous factors such as ionized calcium, 
high glucose, inflammation, oxidative stress, activation of RAAS, uremic toxins, TGF-
β1 and FGF23 have been shown to reduce Klotho130. High phosphate has also been 
implicated, and healthy mice on a high phosphate diet show significantly reduced renal 
Klotho levels (unpublished data from Study IV). Importantly, the downregulation of 
Klotho in CKD may at least in part be due to epigenetic changes as uremic toxins were 
shown to induce hypermethylation of the KLOTHO gene promoter and reduce renal 
Klotho expression both in vitro and in vivo108,109. 
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 As previously mentioned, activation of vitamin D responsive elements in 
the Klotho gene promotor stimulates increased expression51. In mice with CKD, 
treatment with a vitamin D receptor agonist increases Klotho and decrease vascular 
calcification131. Also hypophosphatemia increases Klotho, as hypomorph Klotho-/- mice 
fed a low phosphate diet regain some Klotho expression52. In a rat model of ageing, 
treatment with a PPARγ agonist increase renal Klotho expression, reduce proteinuria, 
improves GFR, and alleviates cell senescence132. Similarly, correction of blood glucose 
in a murine model of diabetic nephropathy resulted in improved renal function and 
higher levels of Klotho133. Finally, treatment with an angiotensin II inhibitor blocked 
the RAAS-mediated suppression of Klotho, independently of its effects on blood 
pressure134. Whether these are direct effects on Klotho expression or mediated by 
improved renal function is currently unknown. 
 
 
5.3.4 FGF23-Klotho dysregulation 
The reduction in Klotho appears to temporally coincide with the rise in FGF23, and this 
chicken-and-egg conundrum in CKD is not yet solved. Regardless of which comes 
first, the mutual regulation by high FGF23 and low Klotho forms a vicious spiral that 
results in extreme FGF23 concentrations and severe Klotho deficiency in advanced 
stages of CKD. The disturbances in the FGF23-Klotho axis may in turn aggravate 
abnormalities in mineral metabolism, including 1,25(OH)2D deficiency,  
hyperphosphatemia and development of sHPT. All these factors, individually and in 
combination, contribute to CKD progression and development of associated 
complications such as bone disease, vascular calcification and increased mortality135. 
 
 
5.3.5 FGF23 as a pathogenic factor 
In addition to promoting secondary changes in mineral metabolism, a fundamental 
question is if the high FGF23 in CKD is toxic and contribute directly to adverse clinical 
outcome. A couple of recent studies have evaluated the potential impact of FGF23 
excess on end-organ damage. Faul et al showed that intramyocardial and intravenous 
administration of FGF23 results in cardiomyocyte proliferation and left ventricular 
hypertrophy. Importantly, cardiomyocytes does not express Klotho and the effects on 
cell growth were mediated by the PLC pathway in a Klotho-independent manner110. 
However intriguing, these findings need to be validated in additional studies. In a study 
by Lim et al in vitro treatment with FGF23 decreased vascular calcification in human 
vascular smooth muscle cells in a Klotho-dependent fashion136. Notably, these data are 
controversial and other reports do not see Klotho expression in the vasculature, or any 
direct effects on the calcification process by FGF23137,138. In a recent study by Kawai et 
al FGF23 was shown to suppress chondrocyte proliferation and linear growth of 
metatarsals in the presence of soluble Klotho139. This could be of potential clinical 
importance as pediatric CKD patients with high FGF23 levels suffer from disturbed 
longitudinal growth. Finally, it was reported that FGF23 inhibits CYP27B1 in 
monocytes, thus decreasing the local conversion of 25(OH)D to 1,25(OH)2D, which 
may be a key determinant of immune response in CKD patients45. In conclusion, high 
FGF23 predicts mortality and poor clinical outcome in CKD, and emerging evidence 
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indicates a direct pathogenic role in end-organ dysfunction. Given that FGF23 evokes 
organ toxicity, lowering FGF23 levels in CKD may be a viable therapeutic option. 
Indeed, treatment with neutralizing FGF23 antibodies improved the bone phenotype 
and attenuated the sHPT in a rat model of CKD-MBD, but simultaneously resulted in 
hyperphosphatemia, increased vascular calcification and associated mortality140. Of 
note, treatment with neutralizing antibodies leads to undetectable FGF23 levels, and 
there may still be beneficial effects by a moderate lowering of FGF23 in advanced 
CKD. In this regard, Moe recently presented preliminary data that treatment with c-
terminal FGF23, in its proposed role as a competitive inhibitor to intact FGF23, 
improved the biochemical phenotype and increased survival in 5/6 nephrectomised 
mice (oral presentation, ISN Nexus 2012, Copenhagen). 
 
 
5.3.6 Klotho and adverse outcome 
The impact of Klotho deficiency on CKD progression, and the potential role of its 
replacement, has been extensively investigated in rodents. In 2007 Haruna et al 
crossbred mice overexpressing Klotho with a glomerulonephritis mouse model141. Mice 
overexpressing Klotho had markedly prolonged survival and dramatic improvements in 
renal function with fewer morphological lesions, compared to mice with a wild-type 
background. Similarly, viral delivery of the Klotho gene lead to improved creatinine 
clearance, decreased proteinuria and amelioration of the tubulointerstitial damage in a 
model of angiotensin II-induced renal failure134. Expression of Klotho is severely 
reduced in spontaneous hypertensive rats, and viral delivery decrease blood pressure 
and improves kidney histology142. Hu et al induced renal injury in mice with low, 
normal or high Klotho expression143. Mice with low Klotho expression (Klotho+/-) were 
more susceptible to renal damage and developed a more severe renal dysfunction 
compared to wild-type mice. Conversely, mice overexpressing Klotho were more 
resistant to acute renal damage and maintained renal function to a higher extent. A 
similar protective effect against renal dysfunction was seen in mice given recombinant 
Klotho protein shortly after induction of AKI. In a recent study by Zhou et al, Klotho 
was found to be an endogenous antagonist of Wnt/β-catenin-signalling60. Loss of 
Klotho in CKD was closely associated to increased fibrosis and β-catenin activity. 
Conversely, in vivo overexpression of soluble Klotho (both cKL and sKL) inhibited the 
activation of renal β-catenin and ameliorated renal fibrosis in two different mouse 
models of renal failure. Finally, Hu et al showed that overexpression of Klotho 
decreases CKD-associated vascular calcification, both by lowering serum phosphate 
and by directly acting on the vasculature98. In conclusion, these results indicate that 
Klotho deficiency aggravates and Klotho overexpression attenuates renal injury and 
associated complications, both in AKI and in CKD.  
 
An updated summary of the endocrine effects of FGF23 and soluble Klotho is shown in 
Figure 13, and a proposed model of FGF23–Klotho dysregulation in CKD, and its 
adverse effects, is presented in Figure 14. 
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Figure 14. The vicious circle of fibroblast growth factor-23 (FGF23)-Klotho dysregulation in CKD-
MBD. Circulating FGF23 increases whereas tissue level of Klotho decreases in parallel with declining 
kidney function. The link between reduced renal function and increased FGF23 is unknown but may 
involve local mechanisms in bone as well as kidney-derived factors including reduced soluble Klotho. 
Multiple factors in the uremic milieu contribute to Klotho suppression. The loop of FGF23–Klotho 
dysregulation may also be aggravated by a putative FGF23-mediated suppression of Klotho. High FGF23 
is associated with cardiovascular disease, mortality and CKD progression rate in a number of 
epidemiological studies. A causal relationship is supported by experimental studies linking both FGF23 
excess and Klotho deficiency to end-organ damage. Adapted from Olauson H and Larsson TE135. 
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5.3.7 Phosphate toxicity 
Disturbances in FGF23 and Klotho cannot be excluded as potential targets for 
intervention in CKD. However, the adverse effects of a disrupted FGF23-Klotho axis 
are at least partially mediated by secondary changes in mineral metabolism. Both 
Fgf23-/- and Klotho-/- mice suffer from hypercalcemia, hyperphosphatemia and elevated 
1,25(OH)2D levels. In order to dissect the impact of these abnormal parameters, several 
“rescue experiments” have been conducted. Both dietary and genetic disruption of 
1,25(OH)2D activity ameliorates the phenotypes in Fgf23-/- and Klotho-/- mice144-147. 
However, these interventions simultaneously lower serum calcium and phosphate, 
making it difficult to assess the contribution of the individual factors. In mice where 
both Klotho and Npt2a is deleted (Klotho-/-/Npt2a-/-), the hyperphosphatemia is 
reversed through increased renal phosphate wasting, whereas serum calcium and 
1,25(OH)2D are even further elevated compared to in Klotho-/- mice148. Despite 
persistent high levels of calcium, 1,25(OH)2D and FGF23, the lowering of serum 
phosphate results in regained fertility, increased body weight, suppressed ectopic 
calcification and prolonged survival. Importantly, when hyperphosphatemia is 
reintroduced in these mice through dietary means the premature ageing phenotype 
reappears. Excessive dietary phosphate has also been shown to directly impair renal 
function by inflicting tubulointerstitial damage, in animals as well as in humans149,150. 
The mechanism by which phosphate induce renal damage is not clear, but it has been 
speculated that high phosphate in the tubular fluid forms insoluble crystals together 
with calcium, and that these crystals promote tubular injury and progression of CKD. 
Calcium-phosphate crystals are also deleterious to vascular smooth muscle cell function 
and induce vascular calcification151. In conclusion, there is compelling evidence that 
phosphate is a potent toxin that contributes to adverse outcome. This is further 
supported by numerous epidemiological studies showing that high phosphate, even 
within the normal range, is associated with increased cardiovascular morbidity and 
mortality3,4,152,153. 
 
 
5.3.8 Targeting hyperphosphatemia 
Lowering serum phosphate by restricting dietary intake or using phosphate-binders is a 
well-established therapy in late CKD154. Although epidemiological data indicates 
improved survival by the use of phosphate-binders in CKD155,156, it has been difficult to 
prove beneficial effects in RCTs157. There may be several reasons for this. Current 
guidelines recommend the use of phosphate-binders to treat hyperphosphatemia in 
advanced stages of CKD79. As previously discussed, prevalent hyperphosphatemia is a 
rather late occurring event in the development of CKD-MBD, and a single intervention 
at that point may be insufficient to attenuate the poor outcome. Further, compliance is 
rather low, and as many as >50% of the patients don’t take the medication as 
prescribed158. Finally, the phosphate-binding capacity of current agents in relation to 
gastrointestinal side effects is suboptimal, and high doses are often required to achieve 
and maintain normophosphatemia. To overcome these obstacles, earlier initiation of 
treatment, development of more efficient phosphate-lowering modalities such as Npt2b 
inhibitors and simultaneous intervention against several targets may be feasible 
strategies to improve outcome.  
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Also, measurement of FGF23 has been proposed for patient enrichment in 
clinical trials, i.e. that individuals with high FGF23 are most likely to benefit from early 
intervention and should be targeted at earlier stages126. However, the benefits of 
monitoring FGF23, and to use it for selection of treatment and clinical decision-
making, remain to be proven. 
 
 
5.3.9 Klotho and cancer 
It should be mentioned that Klotho, in addition to its role in mineral metabolism, has 
been implicated as a tumour suppressor gene in various cancers, including breast159, 
pancreatic160, lung161 and gastric162 cancers. Briefly, Klotho is downregulated through 
epigenetic silencing in many tumours, and its restoration inhibits proliferation and 
induces apoptosis of tumour cells. However, the potential role for Klotho in cancer was 
not the scope of the present thesis, and is discussed in detail elsewhere163. 
 
 
5.4 FUTURE PERSPECTIVES 
5.4.1 Exploring parathyroid signalling 
Given the results from Study I and II, further investigation of the role of the 
calcineurin-NFAT pathway in PTH regulation is warranted to elucidate its 
physiological significance. This could be achieved through studies of human 
parathyroid tissue, and/or by generating parathyroid-specific calcineurin or NFAT 
knockout mice. If proven relevant it could affect the choice of immunosuppressive 
therapy, i.e. non-calcineurin inhibitors, in transplanted patients with persistent sHPT to 
avoid blocking the calcineurin/NFAT pathway. 
The function of parathyroid Klotho should also be further examined. Standard 
rodent chows contain calcium and vitamin D far exceeding the recommended daily 
intake, which may mask a potential impact of parathyroid Klotho on calcium 
metabolism. Thus, long-term sustained challenges, such as exposure to calcium and 
vitamin D depleted diets, would be informative.  
 
 
5.4.2 A distal-to-proximal tubular mechanism 
The initial FGF23 binding and signalling occurs in distal tubules whereas phosphate 
reabsorption is confined to proximal tubules. The sequence of events from distal tubule 
FGF23 signalling to proximal tubule phosphate transport is unclear. Although our data 
in Study IV clearly indicates regulation of brush-border membrane abundance of Npt2a 
by distal tubular Klotho, the factors involved in such proposed distal-to-proximal tubule 
mechanism are unknown. Also, some studies report on expression of Klotho in the 
renal proximal tubule55,116, although the biological significance is unclear. Further 
studies are warranted to elucidate this putative paracrine mechanism. 
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5.4.3 Shedding and alternative splicing of Klotho 
The circulatory level of Klotho defines its endocrine actions, and is the sum of the two 
soluble isoform (sKL and cKL). However, the alternative splicing of the Klotho gene 
and the shedding of mKL are poorly characterized events. The ratio of these isoforms 
in humans is currently unknown. Accordingly, it is of major importance for the 
understanding of endocrine Klotho to define the regulatory processes behind alternative 
splicing and mKL shedding respectively. This could be achieved by employing a 
combination of different methods. First, in vitro studies of cell lines expressing Klotho, 
endogenously or through transfection, would shed light over the cellular mechanism(s) 
governing shedding and alternative splicing. Second, ex vivo studies of kidney slices, 
from healthy subjects and subjects with CKD, could be used to translate these results 
into a whole-organ setting. Third, transgenic mice with point mutations in the Klotho 
gene to prevent alternative splicing and cell surface shedding could be generated to 
differentiate the impact of the two circulatory isoforms of Klotho in vivo. Finally, novel 
techniques to accurately determine the circulatory levels of sKL and cKL in health and 
in CKD are warranted. 
 
 
5.4.4 Future pharmacological studies 
There is an unacceptable high morbidity and mortality in CKD, and compelling 
evidence point to disturbances in mineral metabolism as key contributing factors. 
Previous RCTs have targeted hyperphosphatemia, 1,25(OH)2D deficiency and sHPT 
mainly in dialysis patients, but despite correction of the biochemical parameters the 
studies have failed to demonstrate beneficial effects on hard clinical outcomes157,164,165. 
Klotho deficiency may be an alternate target of interest. To this end, two main options 
emerge; direct substitution of Klotho protein or treatment with drugs increasing 
endogenous Klotho expression. Among the compounds known to induce Klotho 
several are already in use to treat CKD patients. It is plausible that part of the potential 
beneficial effects by RAAS inhibition, vitamin D receptor activators and reduced 
dietary phosphate uptake is due to increased Klotho levels. Additional treatment 
options including PPARγ agonists and suppressors of hypermethylation need to be 
further examined. Several pharmaceutical companies are currently evaluating the 
therapeutic potential of soluble Klotho in CKD, although still only at the experimental 
stage. Nevertheless, if proven safe and efficient, soluble Klotho could be an important 
and much needed addition to the current therapeutic arsenal in CKD. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kronisk njursjukdom (chronic kidney disease; CKD) är ett samlingsnamn för bestående 
njurskada med eller utan minskad filtrationsförmåga, oavsett bakomliggande orsak. 
Såväl nyinsjuknandet som förekomsten av CKD har ökat i takt med att befolkningen 
åldrats och att andra riskfaktorer förknippade med CKD, t.ex. diabetes och högt 
blodtryck, blivit allt vanligare. Upp till 15 % av befolkningen i västvärlden beräknas 
idag vara drabbade av CKD. Trots att CKD för de allra flesta är ett symtomfritt tillstånd 
medför även en måttligt nedsatt njurfunktion en ökad risk för bl.a. hjärt-kärlsjukdom. 
En bidragande orsak till detta är de störningar i kalcium- och fosfatbalansen som 
uppstår då njurarnas filtrationsförmåga avtar. Parallellt med att njurfunktionen 
försämras utvecklas även sekundära hormonella rubbningar, såsom brist på vitamin D 
och förhöjda nivåer av bisköldkörtelhormon (sekundär hyperparathyroidism).  
Hormonet FGF23 och dess ko-receptor Klotho är två nyligen identifierade 
faktorer med centrala roller i mineralmetabolismen. FGF23 ökar utsöndringen av fosfat 
i urinen, hämmar aktiveringen av vitamin D och minskar sekretionen av 
bisköldkörtelhormon. Vid CKD ökar nivåerna av FGF23 kraftigt, och vävnadsnivåerna 
av Klotho sjunker. Kliniska studier har visat ett starkt samband mellan förändrade 
nivåer av FGF23 och Klotho vid CKD och risken för komplikationer som hjärt-
kärlsjukdom, snabbare förlust av njurfunktion och försämrad överlevnad. 
Syftet med denna avhandling har varit att klargöra FGF23s och Klothos 
funktioner i njurarna och i bisköldkörtlarna, såväl i normal fysiologi som vid CKD. Vi 
har tillämpat en translationell forskningsmetodik och kombinerat kliniska studier med 
molekylärbiologiska metoder och framtagande av genetiskt modifierade djurmodeller.  
Sammanfattningsvis visar vi att vävnadsuttrycket av Klotho är minskat i 
bisköldkörtlarna hos patienter med CKD och sekundär hyperparathyroidism, och att 
höga nivåer av FGF23 direkt bidrar till att sänka Klotho-uttrycket. Vi påvisar en ny 
mekanism för hur FGF23 signalerar i bisköldkörtlarna oberoende av Klotho, vilket har 
stor principiell betydelse för andra biologiska effekter av FGF23. Vi utvecklar även en 
ny modell av njursvikt hos mus som utgör ett värdefullt verktyg för experimentella 
studier av rubbningar i kalcium- och fosfatomsättningen vid CKD. Avslutningsvis 
påvisar vi centrala funktioner för Klotho i njurarna beträffande det renala återupptaget 
av fosfat och regleringen av FGF23. 
Denna avhandling bidrar till en ökad förståelse för kroppens hantering av 
kalcium och fosfat och hur denna förändras vid CKD genom ändrade nivåer och 
funktioner av FGF23 och Klotho. Vidare har vi tagit fram ett antal metodologiskt 
viktiga redskap för framtida studier inom detta forskningsfält.  
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